Risk Factors Associated with Osteopenia/Osteoporosis in Antiretroviral Therapy Naive HIV Patients
  • * (Excluding Mailing and Handling)

Abstract

Introduction/Objectives: Different ART (antiretroviral therapy) options may affect the risk of osteopenia/osteoporosis in people living with HIV (PLWH) having increased life expectancy. Current guidelines recommend bone mineral density (BMD) measurement only in patients at risk. In our study, we investigated the prevalence of osteopenia/osteoporosis and associated risk factors in naive patients not receiving ART.

Methods: This study included 116 newly diagnosed, ART naive HIV-positive patients who were studied retrospectively. Vitamin D level, BMD measurement, CD4 and CD8 count, CD4/CD8 ratio, HIV RNA level, body mass index and other risk parameters of ART naive patients were included in our study.

Results: Of 116 patients, 103 were male and 13 female. 47.4% (osteoporosis in 4.3%, osteopenia in 43.1%) of patients had osteopenia/osteoporosis. The patients with osteopenia/osteoporosis had older age (39.2±11.0 vs 32.0±8.6, p=0.0001), lower vitamin D levels (16.0±5.0 vs 24.4±6.3, p=0.0001), lower BMI (body mass index) (23.0±4.0 vs 24.6±4.6 p<0.05), lower CD4 and CD8 counts (405.1±885.0 vs 467.3± 695.1; 849.9570.4 vs 1012.0±629.4 respectively, p<0.05). 41.8% had CD4 count ≤200/μL (vs 18.0%, p=0.005). No statistically significant differences were observed in terms of gender distribution, smoking, alcohol and drug use, comorbidities and, additional drug use and HIV RNA >100 000 copies/ml. In multivariate analysis, age and vitamin D level were significant and independent (p<0.05) risk factors with osteoporosis/osteopenia.

Conclusion: Being over 40 years of age, CD4 count ≤200/μL, vitamin D level <20 ng/mL and low BMI are the most important risk factors for osteopenia/osteoporosis in ART naive patients. Among these parameters, age and vitamin D level were significant and independent risk factors. These factors may guide the determination of the need for dual-energy x-ray absorptiometry (DXA) testing in ART naive patients and drug choices in the treatment plan.

[1]
Alvarez E, Belloso WH, Boyd MA, et al. Which HIV patients should be screened for osteoporosis. Curr Opin HIV AIDS 2016; 11(3): 268-76.
[http://dx.doi.org/10.1097/COH.0000000000000269] [PMID: 26895510]
[2]
Shiau S, Broun EC, Arpadi SM, Yin MT. Incident fractures in HIV-infected individuals. AIDS 2013; 27(12): 1949-57.
[http://dx.doi.org/10.1097/QAD.0b013e328361d241] [PMID: 24126140]
[3]
Cotter AG, Sabin CA, Simelane S, et al. Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS 2014; 28(14): 2051-60.
[http://dx.doi.org/10.1097/QAD.0000000000000353] [PMID: 25265073]
[4]
Antela A, Aguiar C, Compston J, et al. The role of tenofovir alafenamide in future HIV management. HIV Med 2016; 17(S2) (Suppl. 2): 4-16.
[http://dx.doi.org/10.1111/hiv.12401] [PMID: 26952360]
[5]
Pramukti I, Lindayani L, Chen YC, et al. Bone fracture among people living with HIV: A systematic review and meta-regression of prevalence, incidence, and risk factors. PLoS One 2020; 15(6): e0233501.
[http://dx.doi.org/10.1371/journal.pone.0233501] [PMID: 32497105]
[6]
EACS. Guidelines version 12.0 October 2023. 2023. Available From: https://www.eacsociety.org/media/guidelines-12.0.pdf
[7]
Biver E. Osteoporosis and HIV infection. Calcif Tissue Int 2022; 110(5): 624-40.
[http://dx.doi.org/10.1007/s00223-022-00946-4] [PMID: 35098324]
[8]
Borgström F, Karlsson L, Ortsäter G, et al. Fragility fractures in Europe: Burden, management and opportunities. Arch Osteoporos 2020; 15(1): 59.
[http://dx.doi.org/10.1007/s11657-020-0706-y] [PMID: 32306163]
[9]
Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 2022; 17(1): 58.
[http://dx.doi.org/10.1007/s11657-022-01061-5] [PMID: 35378630]
[10]
Serrano S, Mariñoso ML, Soriano JC, et al. Bone remodelling in human immunodeficiency virus-1-infected patients. A histomorphometric study. Bone 1995; 16(2): 185-91.
[http://dx.doi.org/10.1016/8756-3282(94)00028-X] [PMID: 7756046]
[11]
Ramalho J, Martins CSW, Galvão J, et al. Treatment of human immunodeficiency virus infection with tenofovir disoproxil fumarate containing antiretrovirals maintains low bone formation rate, but increases osteoid volume on bone histomorphometry. J Bone Miner Res 2019; 34(9): 1574-84.
[http://dx.doi.org/10.1002/jbmr.3751] [PMID: 31269294]
[12]
Mansueto P, Seidita A, Vitale G, Gangemi S, Iaria C, Cascio A. Vitamin D deficiency in HIV infection: Not only a bone disorder. BioMed Res Int 2015; 2015: 1-18.
[http://dx.doi.org/10.1155/2015/735615] [PMID: 26000302]
[13]
Ceballos ME, Carvajal C, Jaramillo J, Dominguez A, González G. Vitamin D and bone mineral density in hiv newly diagnosed therapy-naive patients without any secondary causes of osteoporosis. Calcif Tissue Int 2019; 104(1): 42-9.
[http://dx.doi.org/10.1007/s00223-018-0474-5] [PMID: 30209528]
[14]
Hileman CO, Overton ET, McComsey GA. Vitamin D and bone loss in HIV. Curr Opin HIV AIDS 2016; 11(3): 277-84.
[http://dx.doi.org/10.1097/COH.0000000000000272] [PMID: 26890209]
[15]
Mascarau R, Bertrand F, Labrousse A, et al. HIV-1-infected human macrophages, by secreting RANK-L, contribute to enhanced osteoclast recruitment. Int J Mol Sci 2020; 21(9): 3154.
[http://dx.doi.org/10.3390/ijms21093154] [PMID: 32365752]
[16]
Aydın OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazlıcan O. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. Braz J Infect Dis 2013; 17(6): 707-11.
[http://dx.doi.org/10.1016/j.bjid.2013.05.009] [PMID: 24076108]
[17]
Aydın Ö, Ankaralı H, Ergen P, Betül Baysal N, Çağ Y. The evaluation of risk factors related to reduced bone mineral density in young people living with HIV. Afr Health Sci 2022; 22(4): 461-9.
[http://dx.doi.org/10.4314/ahs.v22i4.52] [PMID: 37092088]
[18]
Gupta P, Singh S, Mahto S, et al. Prevalence and predictors of low bone mineral density in treatment-naive HIV-infected patients and its correlation with CD4 cell counts. Tzu-Chi Med J 2021; 33(1): 49-54.
[http://dx.doi.org/10.4103/tcmj.tcmj_177_19] [PMID: 33505878]
[19]
Atencio P, Cabello A, Conesa-Buendía FM, et al. Increased risk factors associated with lower BMD in antiretroviral-therapy–naïve HIV-infected adult male. BMC Infect Dis 2021; 21(1): 542.
[http://dx.doi.org/10.1186/s12879-021-06263-9] [PMID: 34107907]
[20]
Hoy JF, Grund B, Roediger M, et al. Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: Findings from the START bone mineral density substudy, a randomized trial. J Bone Miner Res 2017; 32(9): 1945-55.
[http://dx.doi.org/10.1002/jbmr.3183] [PMID: 28650589]